https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/?source=iedfolrf0000001
Feb 17, 2024 - Even a modest starting investment in the right stocks could pay off in the years ahead.
0
fool:2106393398410223638
0
https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001
Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long.
0
fool:759506756515710012
0
https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 21, 2024 - These stocks are used to beating the market.
0
fool:-3479996822515701876
0
https://www.zacks.com/stock/news/2193528/eyepoint-eypt-surges-178-on-upbeat-phase-ii-eye-disease-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193528
Dec 05, 2023 - EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
zc:7798586859533673735
0
https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-r-d-focus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195113
Dec 07, 2023 - Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
zc:1484433858443186251
0
https://www.zacks.com/commentary/2195370/top-analyst-reports-for-chevron-sap-united-parcel-service?cid=CS-ZC-FT-research_daily-2195370
Dec 08, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), SAP SE (SAP) and United Parcel Service, Inc. (UPS).
zc:-2121452919798845299
0
https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195671
Dec 08, 2023 - Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
zc:9070898926774347693
0
https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204856
Jan 03, 2024 - We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
zc:-6303957344621396969
0
https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196
Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zc:-4643956653710555069
0
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
zc:5632938074738624243
0